Cullinan Therapeutics CGEM Cash Flow Statement (2019-2026)

NASDAQ CGEM
$11.35 +0.12 (+1.07%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Cullinan Therapeutics Quarterly Cash Flow Statement

Periods 28 quarters
Latest Sep 2026

Cullinan Therapeutics reported cash from operations of -$43.08M and free cash flow of -$43.08M for the quarter ended Sep 2026, down 16.8% year over year. This cash flow statement covers 28 quarters of results from Dec 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-34.21M-12.89M174.07M-24.89M-27.09M-58.14M-32.21M-39.18M-25.56M-37.34M-42.03M-40.56M-47.65M-48.50M-70.06M-50.61M-50.71M-49.66M-53.70M-49.39M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.01M0.01M0.01M0.01M0.06M0.07M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.05M
Share-based CompensationStock Comp.
12.15M6.57M8.61M5.27M7.51M7.26M7.92M7.74M7.52M8.23M10.53M9.43M9.63M9.37M9.89M9.47M7.31M7.62M8.45M8.37M
Deferred Taxes
-19.57M
Gains from Sales and DivestituresGains Divest
0.06M
Gains from Investment SecuritiesGains Investment
-0.02M
Other non-cash itemsOther Non-Cash
1.13M0.95M0.79M0.16M-0.60M-1.37M-2.15M-3.02M-3.62M-3.31M-3.73M-4.93M-3.51M-2.31M6.33M-9.39M-0.93M-0.78M2.11M-3.12M
Change in Working Capital
Change in Account PayablesChange Payables
1.15M3.14M-3.21M-1.58M1.15M-0.63M0.46M-1.54M1.54M1.21M-2.15M0.56M-0.43M1.72M-0.94M-0.74M-0.88M1.67M1.22M-2.59M
Change in Accrued ExpensesChange Accrued Exp.
2.77M1.03M4.69M1.23M1.58M2.64M-2.82M5.17M5.06M-7.53M3.60M-0.06M6.89M-5.26M1.61M5.49M6.18M-4.31M4.21M2.07M
Change in TaxesChange Taxes
46.50M-35.10M-7.12M-0.08M-4.21M
Change in Other Operating AssetsOther Assets Change
-1.84M1.14M-0.09M-0.54M0.62M0.76M-1.92M3.81M3.29M-0.41M2.59M-1.34M1.64M-1.74M-3.52M-0.80M-0.84M0.66M-2.09M1.71M
Other Working Capital ChangesOther WC Changes
1.84M-1.14M0.09M0.54M-0.62M-0.76M1.92M-3.81M-3.29M0.41M-2.59M1.34M-1.64M1.74M3.52M0.80M0.84M-0.66M2.09M-1.71M
Cash from OperationsCash from Ops.
-15.17M-21.91M-25.42M-54.35M-24.98M-51.00M-31.01M-34.14M-18.13M-38.25M-36.29M-34.14M-36.63M-43.16M-57.61M-36.88M-38.11M-46.05M-38.22M-43.08M
Investing Activities
Capital ExpendituresCapex
0.25M0.88M0.16M0.05M0.01M
Change in Property, Plant and EquipmentChange in PP&E
-0.25M-0.88M-0.16M-0.05M-0.01M
Purchase of InvestmentsInvestments Purchased
77.26M57.02M36.35M124.13M160.42M89.14M81.45M136.78M66.01M131.37M324.93M168.04M19.60M-138.22M
Sale and Maturity of InvestmentsInvestments Sold
61.40M91.73M67.20M61.40M132.60M104.48M93.61M93.82M117.48M144.33M139.82M116.68M184.00M162.65M131.93M80.00M42.00M52.55M55.25M86.04M
Cash from Investing ActivitiesCash from Investing
-15.86M34.71M300.85M-57.98M-28.61M15.18M12.11M-42.96M51.47M12.96M-185.11M19.88M15.96M36.81M53.40M67.39M22.39M32.41M40.68M51.64M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
0.80M1.40M
Net Long-Term Debt Issued (Repaid)Net LT Debt
0.80M1.40M
Net Debt Issuances and RepaymentsNet Debt Issuance
0.80M1.40M
Change in Capital Stock
Common Stock IssuedStock Issued
2.70M1.59M-1.59M-0.04M38.42M1.09M261.57M0.38M1.10M1.06M
Shares Repurchased
Net Shares Issued and RepurchasedNet Shares Issued
2.70M1.59M-1.59M-0.04M38.42M1.09M261.57M0.38M1.10M1.06M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
0.80M1.40M0.18M1.83M
Net Equity Issued and RepurchasedNet Equity Issued
2.70M2.39M-0.19M0.18M1.79M38.42M1.09M261.57M0.38M1.10M1.06M
Other financing activities (as filed)
-0.92M-0.02M1.18M-34.43M-3.79M-0.66M
Cash from Financing ActivitiesCash from Financing
2.70M3.54M2.01M1.43M-32.91M1.79M38.60M0.11M0.25M1.09M262.20M1.33M1.58M0.37M0.72M0.38M1.10M1.06M
Additional items
Change in Cash
-28.33M16.34M277.45M-110.91M-86.51M-34.02M19.71M-76.99M33.59M-24.21M40.79M-12.94M-19.08M-6.35M-3.84M30.52M-15.00M-13.25M3.56M9.62M
Ending Cash Balance
59.77M76.12M353.56M242.66M156.15M122.13M141.83M64.85M98.43M74.23M115.02M102.09M83.01M76.66M72.82M103.34M88.33M75.08M78.64M88.26M
Free Cash FlowFCF
-15.17M-21.91M-25.42M-54.60M-25.87M-51.16M-31.06M-34.14M-18.13M-38.25M-36.29M-34.14M-36.63M-43.16M-57.61M-36.88M-38.12M-46.05M-38.22M-43.08M
Net Cash FlowNCF
-28.33M16.34M277.45M-110.91M-86.51M-34.02M19.71M-76.99M33.59M-24.21M40.79M-12.94M-19.08M-6.35M-3.84M30.52M-15.00M-13.25M3.56M9.62M
Income Taxes PaidTaxes Paid
32.58M5.22M0.08M4.63M-9.14M-3.87M1.60M-2.97M

Cullinan Therapeutics Cash Flow Statement API

Pull Cullinan Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CGEM&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY